



Abgenix to Present at 6th Annual BIO CEO & Investor Conference

FREMONT, Calif.--(BUSINESS WIRE)--Feb. 18, 2004--Abgenix, Inc. (NASDAQ:ABGX) today announced that the company will present at the 6th Annual BIO CEO & Investor Conference on Wednesday, February 25, 2004 at 11:00 am ET, 8:00 am PT. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of the webcast will also be available on the company's website until Wednesday, March 3, 2004.

Raymond Withy, Ph.D., president and chief executive officer of Abgenix, will provide an update on the company's antibody drug development activities.

About Abgenix

Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

Statements made in this press release about Abgenix's technologies, product development activities, collaborative arrangements and process science and manufacturing activities and about its projected financial results and the achievement of milestone or similar payments, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, product manufacturing, regulatory approval processes, competitive products and services, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

CONTACT: Abgenix, Inc.
Ami Knoefler, 510-284-6350 or 510-284-6605

SOURCE: Abgenix, Inc.